Small Bowel Adenocarcinoma
文献摘要
Small bowel adenocarcinoma is a malignant epithelial neoplasm arising from the glandular mucosa of the duodenum, jejunum, or ileum, distinct from ampullary adenocarcinoma, which is staged and treated separately. Primary small bowel malignant neoplasms are rare. Adenocarcinoma was historically considered the most common histologic subtype, but contemporary population-based registry data indicate that neuroendocrine tumors now equal or exceed adenocarcinoma in overall incidence; adenocarcinoma remains the most common subtype in the duodenum, while neuroendocrine tumors predominate in the ileum. The tumor arises most often in the duodenum, particularly the periampullary portion, where its treatment and prognosis overlap with those of periampullary and pancreaticobiliary malignant neoplasms. Small bowel adenocarcinoma develops through at least 2 molecular routes: a chromosomal instability pathway resembling the colorectal adenoma-carcinoma sequence and a mismatch repair-deficient pathway that occurs proportionally more often in small bowel adenocarcinoma than in colorectal cancer. Diagnosis relies on laboratory studies, cross-sectional imaging, and endoscopic or capsule-based visualization but is frequently delayed because symptoms overlap with more common benign conditions. Treatment requires segmental resection or pancreaticoduodenectomy depending on location, with systemic therapy guided by stage and molecular profile, particularly mismatch repair status. This activity reviews the evaluation and interdisciplinary treatment of small bowel adenocarcinoma, emphasizing the interprofessional collaboration needed to optimize outcomes for this rare malignant neoplasm.